Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Acute Lymphoblastic Leukemia, in Relapse: early-phase trial registry

2 of 3 indexed Acute Lymphoblastic Leukemia, in Relapse trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Acute Lymphoblastic Leukemia, in Relapse: 3 US clinical trials tracked, 2 recruiting.

Acute Lymphoblastic Leukemia, in Relapse is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition acute-lymphoblastic-leukemia-in-relapse

OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Acute Lymphoblastic Leuk (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Acute Lymphoblastic Leukemia, in Relapse

Acute Lymphoblastic Leukemia, in Relapse lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acute Lymphoblastic Leukemia, in Relapse on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acute Lymphoblastic Leukemia, in Relapse is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 13

Phase Distribution

PhaseTrial count
Phase 1 3

Named interventions

Most-linked intervention names on Acute Lymphoblastic Leukemia, in Relapse records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CliniMACS Device
2 trials
Mesna Drug
2 trials
Fludarabine Drug
2 trials
Cyclophosphamide Drug
2 trials
CD19- specific CAR engineered autologous T-cells (SJCAR19 product) Biological
1 trials
CD19-CAR(Mem) T-cells Biological
1 trials
Hydrocortisone Drug
1 trials
Methotrexate Drug
1 trials

US sites by state

Facility locations filed on Acute Lymphoblastic Leukemia, in Relapse trials. A trial with sites in several states counts in each.

Tennessee 2 trials
Massachusetts 1 trials
Illinois 1 trials
Georgia 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acute Lymphoblastic Leukemia, in Relapse page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphoblastic Leukemia, in Relapse condition card totals 3 registered trials; most-linked intervention CliniMACS; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.